These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9345404

  • 21. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F, Reggio A.
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [Abstract] [Full Text] [Related]

  • 22. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group.
    J Neurol Sci; 2005 Dec 15; 239(1):67-74. PubMed ID: 16169561
    [Abstract] [Full Text] [Related]

  • 23. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH.
    Ann Neurol; 1998 Jan 15; 43(1):79-87. PubMed ID: 9450771
    [Abstract] [Full Text] [Related]

  • 24. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ.
    Curr Med Res Opin; 2004 Jan 15; 20(1):25-30. PubMed ID: 14741068
    [Abstract] [Full Text] [Related]

  • 25. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
    León C, Violante A, Arriada N, Santana HR, Corona T.
    Rev Neurol; 2004 Jan 15; 31(11):1019-22. PubMed ID: 11190865
    [Abstract] [Full Text] [Related]

  • 26. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun 15; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 27. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 15; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 28. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 15; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 29. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T, Schwan M, Pollmächer T, Yassouridis A, Uhr M, Trenkwalder C, Weber F.
    Mult Scler; 2007 Nov 15; 13(9):1138-45. PubMed ID: 17967841
    [Abstract] [Full Text] [Related]

  • 30. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 15; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 31. [Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
    Bartosik-Psujek H, Mitosek-Szewczyk K, Belniak E, Stelmasiak Z.
    Pol Merkur Lekarski; 2004 Jul 15; 17(97):28-32. PubMed ID: 15559606
    [Abstract] [Full Text] [Related]

  • 32. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
    J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
    [Abstract] [Full Text] [Related]

  • 33. [Interferon therapy of multiple sclerosis].
    Jensen D.
    Tidsskr Nor Laegeforen; 1999 Sep 10; 119(21):3142-5. PubMed ID: 10522481
    [Abstract] [Full Text] [Related]

  • 34. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Sep 10; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 35. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
    Trojano M, Defazio G, Avolio C, Paolicelli D, Giuliani F, Giorelli M, Livrea P.
    J Neurovirol; 2000 May 10; 6 Suppl 2():S47-51. PubMed ID: 10871785
    [Abstract] [Full Text] [Related]

  • 36. [The treatment of multiple sclerosis with beta-interferon 1a].
    Rivera VM.
    Rev Neurol; 2000 May 10; 31(5):470-1. PubMed ID: 11027100
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 10; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 39. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H, Sahraian MA, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A.
    Acta Neurol Scand; 2007 Jun 10; 115(6):429-31. PubMed ID: 17511854
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.